Hematologic disorders in pregnancy: the role of the complement system.

Key Points

• The aim is to explore the role of the complement system in hematologic disorders during pregnancy and the need for effective interventions.
• Reviewed existing literature on complement inhibitors and their impacts on maternal health.
• Identified biomarkers of complement activity specific to pregnancy.
• Proposed metrics for using complement inhibitors in treatment protocols for TMAs and APS.
• Complement inhibitors significantly reduce maternal morbidity and mortality in conditions like PNH and TMAs.
• Functional biomarkers for monitoring complement activity are crucial for timely intervention.
• Clinical trials are warranted to assess the benefits of complement inhibition in obstetric APS and hypertensive disorders.